Castration-resistant prostate cancer--hormone therapy redux - PubMed (original) (raw)

Editorial

. 2010 Mar 20;28(9):1447-9.

doi: 10.1200/JCO.2009.25.3781. Epub 2010 Feb 16.

• PMID: 20159817
• DOI: 10.1200/JCO.2009.25.3781

Editorial

Castration-resistant prostate cancer--hormone therapy redux

Anthony W Tolcher et al. J Clin Oncol. 2010.

No abstract available

PubMed Disclaimer

Comment on

• Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
  Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI. Danila DC, et al. J Clin Oncol. 2010 Mar 20;28(9):1496-501. doi: 10.1200/JCO.2009.25.9259. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159814 Free PMC article. Clinical Trial.
• Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
  Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. Reid AH, et al. J Clin Oncol. 2010 Mar 20;28(9):1489-95. doi: 10.1200/JCO.2009.24.6819. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159823 Free PMC article. Clinical Trial.
• Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
  Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Ryan CJ, et al. J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159824 Free PMC article. Clinical Trial.

Similar articles

• Intra-prostatic androgen levels during various androgen-blockade regimens.
  Nishiyama T. Nishiyama T. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):229-41. doi: 10.1016/j.beem.2008.01.002. Best Pract Res Clin Endocrinol Metab. 2008. PMID: 18471782 Review.
• Complete androgen blockade for the treatment of prostate cancer.
  Labrie F, Dupont A, Belanger A. Labrie F, et al. Important Adv Oncol. 1985:193-217. Important Adv Oncol. 1985. PMID: 3916740 Review. No abstract available.
• Endocrine therapy for prostate cancer.
  Labrie F. Labrie F. Endocrinol Metab Clin North Am. 1991 Dec;20(4):845-72. Endocrinol Metab Clin North Am. 1991. PMID: 1778180 Review.
• Physiologic basis of endocrine therapy for prostatic cancer.
  McConnell JD. McConnell JD. Urol Clin North Am. 1991 Feb;18(1):1-13. Urol Clin North Am. 1991. PMID: 1899494 Review.
• Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
  Vis AN, Schröder FH. Vis AN, et al. BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. BJU Int. 2009. PMID: 19558559 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information